• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

ALDEA Pharmaceuticals

edit

ALDEA Pharmaceuticals is developing small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) family, to treat toxic aldehyde-related diseases. This proprietary technology represents new product opportunities to address novel targets across multiple therapeutic areas. For example, an ALDH activator compound enhances the detoxification of acetaldehyde in the alcohol metabolism pathway, to treat acute symptoms and to reduce long-term tissue damage and cancer risk.

Recent Milestones

edit

• 
  ALDEA Pharmaceuticals received $7M in Venture Round funding. (5/8/12)
  Posted 4/19/12 at 2:46am via sec.gov
• 
  ALDEA Pharmaceuticals added Wenjin Yang as Co - Founder & VP, Research. (3/1/11)
  Posted 5/8/13 at 3:14pm
• 
  ALDEA Pharmaceuticals added Daria Mochly-Rosen as Founder & Director. (1/1/11)
  Posted 5/2/13 at 5:55pm
• 
  ALDEA Pharmaceuticals added Che-Hong Chen as Founder. (1/1/11)
  Posted 5/2/13 at 5:55pm

Videos

Screenshots

edit

Sources

1. SEC (sec.gov) [edit]